Clinical Trial Update: PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) [Phase 2]

View source ↗

Summary

Phase 2 trial update for PRISM evaluating panitumumab as second-line monotherapy in head and neck cancer; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: Amgen | Conditions: Cancer, Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2016-03-07